ClinicalTrials.gg

Program

RSVt Vaccine

Also written as “Low Dose (LD) RSVt vaccine”, “Standard Dose (SD) RSVt vaccine” and “High Dose (HD) RSVt vaccine”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.

Furthest: phase 3, since Jan 24, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi30 open or runningphase 3since Jan 24, 2024Jan 6, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2023First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT05687279 · 80 enrolled · United States, Puerto Rico
  2. Jan 24, 2024Phase 3 study in RSV ImmunisationNCT06252285 · 6,300 enrolled · United States, Argentina, Brazil and more
  3. Nov 22, 2024Phase 3 study in RSV ImmunisationNCT06705140 · 42 enrolled · Honduras

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RSVt Vaccine”name, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06705140RSV Immunisation · Honduras3TerminatedJun 11, 202542
NCT06252285RSV Immunisation · United States, Argentina, Brazil and more3TerminatedDec 4, 20256,300
NCT05687279Respiratory Syncytial Virus Infections · United States, Puerto Rico2CompletedDec 27, 202480

How it is read

Names in the registry

  • “RSVt Vaccine”, 2 entries
  • “Low Dose (LD) RSVt vaccine”, 1 entry
  • “Standard Dose (SD) RSVt vaccine”, 1 entry
  • “High Dose (HD) RSVt vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.